Featuring Howard J. Shatz, Senior Economist, RAND Corporation; Professor, Pardee RAND Graduate School; Director, RAND-Initiated Research; and Jacob Shapiro, Associate Professor, Politics and International Affairs, and Co-Director, Empirical Studies of Conflict Project, Princeton University; and author of The Terrorist’s Dilemma: Managing Violent Covert Organizations; moderated by John Mueller, Senior Research Scientist, Mershon Center for International Security Studies, Ohio State University, and Senior Fellow, Cato Institute.
Every imaginable product and service has a price, and yet there is something different about pricing prescription medicines. In the new issue of Regulation, Charles L. Hooper and David R. Henderson say that to “fix” drug pricing, we need more competition, more cost sharing, and the liberalization of some regulations. Also in this issue, Larry Downes describes how rent-seeking and public choice have put a telecom deregulation success story at risk, and Jason Scott Johnston looks at the social cost of carbon – how is it derived and how is it used to justify America’s climate policy?
When the Danish newspaper Jyllands-Posten published the cartoons of the prophet Muhammad in 2005, Denmark found itself at the center of a global battle about the freedom of speech. The paper’s culture editor, Flemming Rose, defended the decision to print the 12 drawings, and he quickly came to play a central part in the debate about the limitations to freedom of speech in the 21st century. In The Tyranny of Silence, Flemming Rose provides a personal account of an event that has shaped the debate about what it means to be a citizen in a democracy and how to coexist in a world that is increasingly multicultural, multireligious, and multiethnic.
The Cato Institute has released its 2014 Annual Report, which documents a dynamic year of growth and productivity. “Libertarianism is the philosophy of freedom,” Cato’s David Boaz writes in his book, The Libertarian Mind. “It is the indispensable framework for the future.” And as the new report demonstrates, the Cato Institute, thanks largely to the generosity of our Sponsors, is leading the charge to apply this framework across the policy spectrum.
Featuring Donald Abrams, M.D., Director of Clinical Programs, Osher Center for Integrative Medicine, University of California; Robert DuPont, M.D., President, Institute for Behavior and Health; Rob Kampia, Executive Director, Marijuana Policy Project; Moderated by Tim Lynch, Director, Project on Criminal Justice, Cato Institute
Ten years ago, on March 17, 1999, an important government study was released regarding certain patients’ use of marijuana as prescribed by their doctors. The Institute of Medicine, a branch of the National Academy of Sciences, issued what was then the most comprehensive analysis of the scientific and medical literature about marijuana. The report stated, “The accumulated data indicate a potential therapeutic value for cannabinoid drugs, particularly for symptoms such as pain relief, control of nausea and vomiting, and appetite stimulation.”Many medical experts continue to caution about harms that may result from smoking marijuana, though those harms need to be weighed against other harms that particular patients may be facing. In the political realm, the debate over the legal status of medical marijuana continues to rage. Since 1996, 12 states have legalized marijuana for medical use. What have medical scientists learned about marijuana over the past 10 years? And how have the politics on this contentious issue shifted at the federal and state level? Join us for a lively discussion of the science and politics of medical marijuana.